Orally effective methylphenidate extended release powder and aqueous suspension product
View Patent ↗An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.
1. A powder which when admixed with water forms an aqueous oral suspension, said powder comprising (i) an immediate release methylphenidate component, (ii) a sustained release water-insoluble, water-permeable, pH-independent, barrier coated methylphenidate-ion exchange resin complex, and (iii) a buffering agent which adjusts the pH of the oral aqueous suspension comprising the powder to a pH of about 4.2,
wherein the oral aqueous suspension provides a pharmacokinetic profile in which d-methylphenidate has an area under the curve (AUC) 0-∞ of about 114 ng-hr/mL to about 180 ng-hr/mL and a C max of about 11 ng/mL to about 17 ng/mL following a single oral administration of the oral aqueous suspension to adult subjects under fasted conditions at a dose equivalent to 60 mg racemic methylphenidate HCl.
2. The powder according to claim 1 , wherein the suspension which comprises the powder further comprises at least about 80% of water based on the total weight of the suspension.
3. The powder according to claim 2 , wherein the suspension has less than about 5% loss in potency over a period of about 1 month of storage at room temperature.
4. The powder according to claim 2 , wherein the suspension has less than about 1% of an impurity which is threo-α-phenyl-2-piperidineacetic acid hydrochloride after a period of about 1 month of storage at room temperature.
5. The powder according to claim 2 , wherein the suspension has less than about 5% loss in potency over a period of about 4 months of storage at room temperature.
6. The powder according to claim 2 , wherein the suspension has less than about 1% of an impurity which is threo-α-phenyl-2-piperidineacetic acid hydrochloride after a period of about 4 months of storage at room temperature.
7. The powder according to claim 1 , wherein the methylphenidate in the immediate release methylphenidate component of (i) comprises about 20% w/w of the total methylphenidate in said powder.
8. The powder according to claim 1 , wherein the immediate release methylphenidate component comprises an uncoated methylphenidate-ion exchange resin complex.
9. The powder according to claim 1 , wherein the immediate release methylphenidate component comprises a methylphenidate-ion exchange resin complex having a coating that provides immediate release.
10. The powder according to claim 1 , wherein the barrier coating of the sustained release water-insoluble, water-permeable, pH-independent, barrier coated methylphenidate-ion exchange resin complex comprises a polyvinylacetate polymer and a plasticizer.
11. The powder according to claim 10 , wherein the barrier coating is cured.
12. The powder according to claim 1 , wherein the barrier coating of the sustained release water-insoluble, water-permeable, pH-independent, barrier coated methylphenidate-ion exchange resin complex comprises ethylcellulose.
13. The powder according to claim 1 , wherein the barrier coating of the sustained release water-insoluble, water-permeable, pH-independent, barrier coated methylphenidate-ion exchange resin complex comprises a methyl methyacrylate polymer or co-polymer.
14. The powder according to claim 1 , which provides the aqueous oral suspension comprising at least about 70% of water based on the total weight of the suspension.
15. The powder according to claim 1 , wherein the oral aqueous suspension has a therapeutically effective plasma profile for methylphenidate of about 12 hours following a single oral administration of the oral aqueous suspension to adult subjects under fasted conditions at a dose equivalent to 60 mg racemic methylphenidate HCl.
16. The powder according to claim 1 , wherein the oral aqueous suspension provides a therapeutically effective amount of methylphenidate within 45 minutes after a single oral administration of the oral aqueous suspension to adult subjects under fasted conditions at a dose equivalent to 60 mg racemic methylphenidate HCl.
17. The powder according to claim 1 , wherein the oral aqueous suspension provides a single average plasma concentration peak following a single oral administration of the oral aqueous suspension to adult subjects under fasting conditions at a dose equivalent to 60 mg racemic methylphenidate HCl.
18. The powder according to claim 1 , wherein the oral aqueous suspension provides a T max of about 4 hours to about 5.25 hours following a single oral administration of the oral aqueous suspension to adult subjects under fasted conditions at a dose equivalent to 60 mg racemic methylphenidate HCl.
19. The powder according to claim 1 , wherein following a single oral administration of the oral aqueous suspension to adult subjects at a dose equivalent to 60 mg racemic methylphenidate HCl said suspension provides a reduced T max for d-methylphenidate in adult subjects fed with a high-fat meal prior to administration compared to adult subjects in a fasted state prior to administration.
20. The powder according to claim 19 , wherein following a single oral administration of the oral aqueous suspension at a dose equivalent to 60 mg racemic methylphenidate HCl, the oral aqueous suspension provides a T max for d-methylphenidate reduced by about 60 minutes in adult subjects fed with a high-fat meal prior to administration compared to adult subjects in a fasted state prior to administration.
21. A powder which when admixed with water forms an aqueous oral suspension, said powder comprising (i) an immediate release methylphenidate component, (ii) a sustained release water-insoluble, water-permeable, pH-independent, barrier coated methylphenidate-ion exchange resin complex, and (iii) a buffering agent which adjusts the pH of the oral aqueous suspension comprising the powder to a pH of about 4.2,
wherein the oral aqueous suspension comprising the powder further comprises at least about 80% of water based on the total weight of the suspension,
wherein the oral aqueous suspension has less than about 1% of threo-α-phenyl-2-piperidineacetic acid hydrochloride impurity after a period of about 1 month of storage at room temperature, and
wherein following a single oral administration of the aqueous oral suspension to adult subjects under fasted conditions, at a dose equivalent to 60 mg racemic methylphenidate HCl, the oral aqueous suspension has a pharmacokinetic profile in which d-methylphenidate has
an area under the curve (AUC) 0-∞ of about 114 ng-hr/mL to about 180 ng-hr/mL in adults under fasted conditions,
a C max of about 11 ng/mL to about 17 ng/mL in adults, and
wherein following a single administration of the aqueous oral suspension to adult, the d-methylphenidate has a reduced T max in adults subjects fed with a high-fat meal prior to administration compared to adult subjects in a fasted state prior to administration.
22. The powder according to claim 21 , wherein following a single oral administration of an aqueous oral suspension at a dose equivalent to 60 mg racemic methylphenidate HCl the oral aqueous suspension has a pharmacokinetic profile in which the d-methylphenidate has a T max reduced by about 60 minutes in adults subjects fed with a high-fat meal prior to administration compared to adult subjects in a fasted state prior to administration.